JY
BNTC icon

Jeff Yass’s Benitec Biopharma BNTC Stock Holding History

Jeff Yass’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,908
Closed -$127K – 13411
2026
Q1 		$127K Buy
+11,908
New +$138K ﹤0.01% 12171
2025
Q3 		– Sell
-17,728
Closed -$207K – 12431
2025
Q2 		$207K Sell
17,728
-208,368
-92% -$2.92M ﹤0.01% 11138
2025
Q1 		$2.94M Buy
226,096
+201,324
+813% +$2.44M ﹤0.01% 4693
2024
Q4 		$313K Buy
+24,772
New +$268K ﹤0.01% 9751
2022
Q3 		– Sell
-3,170
Closed -$62K – 13178
2022
Q2 		$62K Buy
+3,170
New +$73.7K ﹤0.01% 11841
2019
Q3 		– Sell
-291
Closed -$55K – 10159
2019
Q2 		$55K Buy
291
+12
+4% +$4.87K ﹤0.01% 9821
2019
Q1 		$135K Buy
279
+53
+23% +$22.8K ﹤0.01% 8120
2018
Q4 		$87K Buy
226
+91
+67% +$50.3K ﹤0.01% 8279
2018
Q3 		$84K Sell
135
-135
-50% -$92.2K ﹤0.01% 8665
2018
Q2 		$137K Buy
270
+50
+23% +$33.8K ﹤0.01% 8901
2018
Q1 		$166K Buy
220
+143
+186% +$120K ﹤0.01% 8457
2017
Q4 		$58K Buy
+77
New +$53.8K ﹤0.01% 8869

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Jeff Yass's BNTC Position: Q2 2026 in Review

Jeff Yass sold out of Benitec Biopharma (BNTC) in Q2 2026, closing a stake of 11,908 shares — an estimated $127K sold.

Jeff Yass first reported a position in BNTC in Q4 2017 and held it in 12 quarters. The position peaked at $2.94M in Q1 2025. 86 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Jeff Yass reported no remaining Benitec Biopharma position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 11,908 Benitec Biopharma shares in Q2 2026, an estimated $127K.
  • Jeff Yass first reported a position in Benitec Biopharma in Q4 2017 and held it in 12 quarters.
  • Jeff Yass's Benitec Biopharma position peaked at $2.94M in Q1 2025.
  • 86 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.